This week’s newsletter covers the science of cannabis strain classification, new CBD research on rheumatoid arthritis and drug-resistant epilepsy, the relationship between adolescent cannabis use and psychosis, and a look at U.S. hemp imports in 2024.
Noteworthy Read
Waking From the Strain Dream: Cannabis Science at a Crossroads (Rolling Stone)
This insightful article by Jahan Marcu, Ph.D., critiques the outdated strain classification system, arguing that Indica/Sativa labels fail to reflect the true chemical complexity of cannabis. He calls for a shift toward data-driven chemovar classification, emphasizing standardized testing and research to enhance consumer understanding and industry precision.
More Noteworthy Reading
CBD Ameliorates Rheumatoid Arthritis by Modulating Gut Microbiota (PubMed)
A study finds that CBD reduces inflammation and symptoms of rheumatoid arthritis by influencing gut microbiota, highlighting a potential new mechanism for cannabinoid-based therapies.
CBD Helpful for All Adults with Drug-Resistant Epilepsy (PubMed)
Research confirms that CBD is effective in reducing seizure frequency in adults with drug-resistant epilepsy, reinforcing its role as a viable alternative to traditional anticonvulsants.
Adolescent Cannabis & Psychosis (PsyPost)
A study explores the relationship between adolescent cannabis use and psychosis, identifying shared genetic and environmental risk factors while also noting patterns of self-medication.
Medical Marijuana vs. Traditional Pharmaceuticals (LifeCann)
An analysis compares the effectiveness, safety, and side effects of medical marijuana against traditional pharmaceuticals, exploring the growing preference for cannabis-based treatments.
Read more
View more in Drug Interactions
US Hemp Import Tallies for 2024 (HempGazette)
New data reveals the scale of U.S. hemp imports in 2024, shedding light on global supply chains, regulatory trends, and domestic production challenges.
Research Round-Up
Medicinal Cannabis & the Intestinal Microbiome (Pharmaceuticals)
This study examines the interactions between medicinal cannabis and the gut microbiome, suggesting potential therapeutic implications for digestive and inflammatory diseases.
Read more
View more in Endocannabinoid System
A heartfelt thank you to all of the CBD brands whose generous support empowers Project CBD to bring you the latest in plant medicine research and journalism every week — we couldn’t do it without you.
